Physician profile
Nicole Egan
NPI 1740023662
$2,140.74
in general payments reported to CMS, 2019-2025
17 companies · $900 in 2025
The $900 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,241 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,140.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $899.88 | 2024-2025 | Avvigo Guidance System, Opticross 6, Wolverine Coronary Cutting Balloon |
| Merck Sharp & Dohme LLC | $233.36 | 2024-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $147.84 | 2024-2025 | Camzyos, Eliquis |
| Biotronik INC. | $147.54 | 2025 | Biomonitor |
| Scpharmaceuticals INC. | $134.36 | 2024-2025 | |
| Esperion Therapeutics, INC. | $125.60 | 2024-2025 | Nexletol |
| Novo Nordisk INC | $106.90 | 2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $73.11 | 2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $58.59 | 2024 | |
| Alnylam Pharmaceuticals INC. | $48.15 | 2024 | Amvuttra |
| Glaxosmithkline, LLC. | $36.11 | 2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $30.28 | 2024 | Farxiga |
| Kestra Medical Technology Services, INC. | $24.38 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.81 | 2024 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $18.09 | 2024 | Evkeeza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $17.75 | 2025 | Attruby |
| Novartis Pharmaceuticals Corporation | $15.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.